123 related articles for article (PubMed ID: 3295621)
1. Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Maschmeyer G; Hiddemann W; Kreutzmann H; Wendt F
Onkologie; 1987 Feb; 10(1):18-21. PubMed ID: 3295621
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Liang R; Chan TK; Todd D
Cancer Chemother Pharmacol; 1988; 21(1):68-70. PubMed ID: 3342467
[TBL] [Abstract][Full Text] [Related]
4. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
[TBL] [Abstract][Full Text] [Related]
5. Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Petti MC; Avvisati G; Tafuri A; Meloni G; Amadori S; Mandelli F
Ann N Y Acad Sci; 1987; 511():436-41. PubMed ID: 3326472
[No Abstract] [Full Text] [Related]
6. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
7. AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
Maschmeyer G; Willborn K; Heit W
Leuk Lymphoma; 1992 Nov; 8(4-5):365-9. PubMed ID: 1290961
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
9. Treatment of recurrent promyelocytic leukemia with a combination regimen utilizing amsacrine, cytosine arabinoside and 6-thioguanine (AAT).
Avvisati G; Petti MC; Petrucci MT; Falconi E; Tirindelli MC; Mandelli F
Haematologica; 1989; 74(3):279-82. PubMed ID: 2511097
[TBL] [Abstract][Full Text] [Related]
10. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
11. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091
[TBL] [Abstract][Full Text] [Related]
12. The use of amsacrine plus intermediate-dose cytosine arabinoside in relapsed and refractory acute nonlymphocytic leukemia.
Dekker AW; Punt K; Verdonck LF
Haematol Blood Transfus; 1987; 30():333-5. PubMed ID: 3623240
[No Abstract] [Full Text] [Related]
13. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Daenen S; Löwenberg B; Sonneveld P; van Putten WL; Verhoef G; Verdonck LF; van Veldhoven M; Huijgens PC
Leukemia; 1994 Jan; 8(1):6-10. PubMed ID: 8289499
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G
Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Dekker AW; Nieuwenhuis HK; Verdonck LF
Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
[TBL] [Abstract][Full Text] [Related]
19. [Effects of alternating as well as long-term intensive polychemotherapy in the remission-maintaining treatment of patients with acute myelocytic leukemia].
Hansz J; Bajko G; Woźny T; Drozdowska D
Pol Arch Med Wewn; 1992 Feb; 87(2):127-33. PubMed ID: 1523139
[TBL] [Abstract][Full Text] [Related]
20. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
